JW Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
JW Pharmaceutical has a total shareholder equity of ₩265.4B and total debt of ₩143.1B, which brings its debt-to-equity ratio to 53.9%. Its total assets and total liabilities are ₩645.0B and ₩379.6B respectively. JW Pharmaceutical's EBIT is ₩96.6B making its interest coverage ratio 15.5. It has cash and short-term investments of ₩94.2B.
Key information
53.9%
Debt to equity ratio
₩143.13b
Debt
| Interest coverage ratio | 15.5x |
| Cash | ₩94.20b |
| Equity | ₩265.44b |
| Total liabilities | ₩379.60b |
| Total assets | ₩645.04b |
Recent financial health updates
Recent updates
JW Pharmaceutical's (KRX:001060) Earnings Are Of Questionable Quality
Mar 21
Is JW Pharmaceutical Corporation (KRX:001060) An Attractive Dividend Stock?
Apr 08How Many JW Pharmaceutical Corporation (KRX:001060) Shares Do Institutions Own?
Mar 13Is JW Pharmaceutical (KRX:001060) Using Too Much Debt?
Feb 15JW Pharmaceutical's(KRX:001060) Share Price Is Down 24% Over The Past Three Years.
Jan 19
Do These 3 Checks Before Buying JW Pharmaceutical Corporation (KRX:001060) For Its Upcoming Dividend
Dec 24Would JW Pharmaceutical Corporation (KRX:001060) Be Valuable To Income Investors?
Nov 30Financial Position Analysis
Short Term Liabilities: A001060's short term assets (₩378.1B) exceed its short term liabilities (₩286.9B).
Long Term Liabilities: A001060's short term assets (₩378.1B) exceed its long term liabilities (₩92.7B).
Debt to Equity History and Analysis
Debt Level: A001060's net debt to equity ratio (18.4%) is considered satisfactory.
Reducing Debt: A001060's debt to equity ratio has reduced from 78% to 53.9% over the past 5 years.
Debt Coverage: A001060's debt is well covered by operating cash flow (60.9%).
Interest Coverage: A001060's interest payments on its debt are well covered by EBIT (15.5x coverage).